增殖扩散TCF1+ CD8+ T cells 的可能路径（一）

ICB等T细胞相关免疫治疗遇到的主要难题之一是T Cell Exhaustion T细胞耗竭。
" k, V* u4 t, p
《Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy》
; O+ a5 _1 r5 R6 T3 ?) |" |8 [, u
“Thus, immune checkpoint blockade relies not on reversal of T cell exhaustion programs, but on the proliferation of a stem-like TIL subset.”
! F8 c& Q6 q) C. A9 n
- E- H; e/ r( O# B0 N6 [ICB免疫治疗与其要靠逆转T细胞耗竭，不如增殖扩散TCF1+ CD8 T细胞。


现搜集整理增殖扩散TCF1+ CD8 T细胞的部分途径如下：
; F& f0 Z( l& r) j+ Z' L' ~7 N# Q
一、表观遗传机制
1、抑制ezh2
《Transient EZH2 suppression by Tazemetostat during in vitro expansion maintains T cell stemness and improves adoptive T cell therapy》
7 ]: Z: s4 o. Y! k8 w/ @
“Tazemetestat induced T cell epigenetic reprogramming and increased the expression of the self-renewing T cell transcription factor TCF1 by reducing its promoter H3K27 methylation preferentially in rapidly dividing T cells.”

0 r. l( i8 J7 I* XEZH2的靶向药有tazemetostat他泽司他，替代药物有利巴韦林。

: e" J- }5 {1 a7 r  l
2、抑制lsd1
% u0 O$ k2 @- a2 Q# P
. e& t/ w% z0 V8 _/ x2 L. P3 ~: U《LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade》

- y3 @3 d/ \; ~- X0 B, O  t0 M“Here, we demonstrate that histone demethylase LSD1 acts to enforce an epigenetic program in progenitor exhausted CD8+ T cells to antagonize the TCF1-mediated progenitor maintenance and to promote terminal differentiation. Consequently, genetic perturbation or small molecules targeting LSD1 increases the persistence of the progenitor exhausted CD8+ T cells, which provide a sustained source for the proliferative conversion to numerically larger terminally exhausted T cells with tumor-killing cytotoxicity, thereby leading to effective and durable responses to anti-PD1 therapy. ”
' ?; n' T* U$ r- ~
LSD1的替代药物有Tranylcypromine。

3、抑制hdac

《Tcf1 and Lef1 transcription factors establish CD8(+) T cell identity through intrinsic HDAC activity》
, F) w6 z" C" B1 g' U
“Tcf1- and Lef1-deficient CD8(+) T cells exhibit histone hyperacetylation, which can be ascribed to intrinsic histone deacetylase (HDAC) activity in Tcf1 and Lef1.”

HDAC的靶向药有西达本胺等药物，替代药物有丙戊酸、氟桂利嗪。

% h3 t8 r' v$ \二、抑制AXL

7 I& C- s! v9 @( e+ T' Z7 L《AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells》

“Systemic inhibition of Axl results in increased type I interferon secretion from dendritic cells that expanded tumor-associated TCF1+PD-1+CD8 T cells, restoring therapeutic response to PD-1 ICB in KPL tumors.”

AXL抑制剂的靶向药有Merestinib梅沙替尼，替代药物有昂丹司琼、吗丁啉。


4 a6 R+ i3 T. r  z* A" }4 t
三、静脉注射连接新抗原肽和Toll样受体7/8激动剂(SNP-7/8a)的纳米颗粒疫苗
2 e1 u$ o+ J6 f+ n
$ v. M' |8 y, V6 _; e2 u《Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells》
8 e& i" V; g% K' I
, q6 ~2 o6 h3 Y( D3 O! w. k; j“Using a self-assembling nanoparticle vaccine that links neoantigen peptides to a Toll-like receptor 7/8 agonist (SNP-7/8a), we show how the route and dose alter the magnitude and quality of neoantigen-specific CD8+ T cells. Intravenous vaccination (SNP-IV) induced a higher proportion of TCF1+PD-1+CD8+ T cells as compared to subcutaneous immunization (SNP-SC). ”

& L: g9 ~6 F1 J7 r$ x# [) s$ V+ M  J
6 O4 I" [+ l( s  G四、抑制nrp1
7 B5 {; }) ^/ m% Z( c
9 P4 q7 h6 |" A+ B) P6 [《Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity》
) N& g. I* [4 m! u" [
# o- t5 @" g/ i' x, p5 X( A“Here we report that mice with a CD8+ T cell-restricted neuropilin-1 (NRP1) deletion exhibited substantially enhanced protection from tumor rechallenge and sensitivity to anti-PD1 immunotherapy, despite unchanged primary tumor growth. ”
1 v$ c# A! N/ H+ \6 Q: u
3 C; j5 u# B: X9 T3 ONrp1抑制剂的替代药物有普萘洛尔、艾曲波帕、格列美脲、西格列汀、度他雄胺、溴隐亭。